NEW YORK (GenomeWeb News) – SynapDx today announced a collaboration with the Broad Institute to develop next-generation sequencing analysis methods to improve autism diagnostics.

Specifically, the techniques will be aimed at improving test accuracy and clinical utility, Lexington, Mass.-based SynapDx said. The company is currently conducting large, prospective, multicenter studies to analyze blood from children who are being clinically evaluated for autism spectrum disorder.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.